doi: 10.1016/0304-3835(90)90106-8.
Transforming growth factor-beta and ovarian carcinoma cells: regulation of proliferation and surface antigen expression
Affiliations
- PMID: 2112423
- DOI: 10.1016/0304-3835(90)90106-8
Item in Clipboard
Transforming growth factor-beta and ovarian carcinoma cells: regulation of proliferation and surface antigen expression
Cancer Lett.
.
Abstract
Transforming growth factor-beta (TGF-beta) is a multifunctional peptide regulating several processes in ovarian cells. The growth of ovarian carcinoma cell lines (OVCAR-3, HTB-77, 2780 and CRL-1572) was reduced by TGF-beta in a dose related manner. The antiproliferative activity was not improved by combination with other biological response modifiers. Treatment with TGF-beta augmented the expression of interferon-gamma induced class I and II antigens of the major histocompatibility complex. The presentation of another antigen namely the tumor marker CA-125 on the cell surface was markedly reduced by TGF-beta.
Similar articles
-
Effects of biological response modifiers on ovarian carcinoma cell lines.Anticancer Res. 1989 Mar-Apr;9(2):461-7. Anticancer Res. 1989. PMID: 2502063
-
Modulation of ovarian carcinoma OV632 antigen by interferons.Oncology. 1992;49(1):53-7. doi: 10.1159/000227011. Oncology. 1992. PMID: 1542495
-
Differential induction by interferons of major histocompatibility complex-encoded and non-major histocompatibility complex-encoded antigens in human breast and ovarian carcinoma cell lines.Cancer Res. 1989 Jun 1;49(11):2928-34. Cancer Res. 1989. PMID: 2497969
-
Different effects of interferons, interleukin-1beta and tumor necrosis factor-alpha in normal (OSE) and malignant human ovarian epithelial cells.Int J Cancer. 1996 Sep 17;67(6):826-30. doi: 10.1002/(SICI)1097-0215(19960917)67:6<826::AID-IJC12>3.0.CO;2-#. Int J Cancer. 1996. PMID: 8824555
-
Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.Clin Cancer Res. 2000 Jun;6(6):2268-78. Clin Cancer Res. 2000. PMID: 10873077 Clinical Trial.
Cited by
-
Transforming growth factor-beta synthesis by human peritoneal mesothelial cells. Induction by interleukin-1.Am J Pathol. 1996 May;148(5):1679-88. Am J Pathol. 1996. PMID: 8623935 Free PMC article.
-
In vivo anti-V-ATPase antibody treatment delays ovarian tumor growth by increasing antitumor immune responses.Mol Oncol. 2020 Oct;14(10):2436-2454. doi: 10.1002/1878-0261.12782. Epub 2020 Sep 10. Mol Oncol. 2020. PMID: 32797726 Free PMC article.
-
Transforming growth factor-beta mRNA expression and growth control of human ovarian carcinoma cells.Br J Cancer. 1992 May;65(5):655-60. doi: 10.1038/bjc.1992.140. Br J Cancer. 1992. PMID: 1586592 Free PMC article.
-
TGF-β isoforms induce EMT independent migration of ovarian cancer cells.Cancer Cell Int. 2014 Sep 9;14(1):72. doi: 10.1186/s12935-014-0072-1. eCollection 2014. Cancer Cell Int. 2014. PMID: 25278811 Free PMC article.
-
Dynamics of protein 27 of avian leukosis virus and transforming growth factor beta2 in lymphoid leukosis susceptible and resistant broiler chicken breeding stock.Vet Res Commun. 1999 May;23(3):191-200. doi: 10.1023/a:1006233818946. Vet Res Commun. 1999. PMID: 10401723
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
